연구동향 분석

Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer

이윤규 이은영 김인호 이근욱 김태민 이세훈 김동완 허대석 2015년

논문상세정보
인용/피인용
' Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • cisplatin
  • small cell lung carcinoma
  • thromboembolism
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,363 0

0.0%

' Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer' 의 참고문헌

  • Thromboembolic events during chemotherapy for germ cell cancer : a cohort study and review of the literature
    Weijl NI J Clin Oncol 18 : 2169 ~ 2178 [2000]
  • Thromboembolic events during chemotherapy for germ cell cancer : a cohort study and review of the literature
    Weijl NI J Clin Oncol 18 2169-2178 [2000]
  • The incidence of venous thromboembolism among patients with primary lung cancer
    Chew HK J Thromb Haemost 6 : 601 ~ 608 [2008]
  • The incidence of venous thromboembolism among patients with primary lung cancer
    Chew HK J Thromb Haemost 6 601-608 [2008]
  • Risk of venous thromboembolism in patients with cancer treated with Cisplatin : a systematic review and meta-analysis
    Seng S J Clin Oncol 30 : 4416 ~ 4426 [2012]
  • Risk of venous thromboembolism in patients with cancer treated with Cisplatin : a systematic review and meta-analysis
    Seng S J Clin Oncol 30 4416-4426 [2012]
  • Risk factors for deep vein thrombosis and pulmonary embolism : a population-based case-control study
    Heit JA Arch Intern Med 160 : 809 ~ 815 [2000]
  • Risk factors for deep vein thrombosis and pulmonary embolism : a population-based case-control study
    Heit JA Arch Intern Med 160 809-815 [2000]
  • Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    Khorana AA Cancer 104 : 2822 ~ 2829 [2005]
  • Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    Khorana AA Cancer 104 2822-2829 [2005]
  • Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
    Numico G Cancer 103 : 994 ~ 999 [2005]
  • Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
    Numico G Cancer 103 994-999 [2005]
  • Prognostic importance of comorbidity in a hospital-based cancer registry
    Piccirillo JF JAMA 291 : 2441 ~ 2447 [2004]
  • Prognostic importance of comorbidity in a hospital-based cancer registry
    Piccirillo JF JAMA 291 2441-2447 [2004]
  • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer : clinical and pharmacogenomic results from SWOG S0124
    Lara PN Jr J Clin Oncol 27 : 2530 ~ 2535 [2009]
  • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer : clinical and pharmacogenomic results from SWOG S0124
    Lara PN Jr J Clin Oncol 27 2530-2535 [2009]
  • Modulation of tissue factor on human monocytes by cisplatin and adriamycin
    Walsh J Br J Haematol 8 : 480 ~ 488 [1992]
  • Modulation of tissue factor on human monocytes by cisplatin and adriamycin
    Walsh J Br J Haematol 8 480-488 [1992]
  • Malignancies, prothrombotic mutations, and the risk of venous thrombosis
    Blom JW JAMA 293 : 715 ~ 722 [2005]
  • Malignancies, prothrombotic mutations, and the risk of venous thrombosis
    Blom JW JAMA 293 715-722 [2005]
  • Increased procoagulant activity of red blood cells in the presence of cisplatin
    Lu CF Chin Med J(Engl) 121 : 1775 ~ 1780 [2008]
  • Increased procoagulant activity of red blood cells in the presence of cisplatin
    Lu CF Chin Med J(Engl) 121 1775-1780 [2008]
  • Incidence of venous thromboembolism and its effect on survival among patients with common cancers
    Chew HK Arch Intern Med 166 : 458 ~ 464 [2006]
  • Incidence of venous thromboembolism and its effect on survival among patients with common cancers
    Chew HK Arch Intern Med 166 458-464 [2006]
  • High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy
    Czaykowski PM J Urol 160 (6Pt 1) : 2021 ~ 2024 [1998]
  • High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy
    Czaykowski PM J Urol 160 6Pt 1 2021-2024 [1998]
  • High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy : a large retrospective analysis
    Moore RA J Clin Oncol 29 : 3466 ~ 3473 [2011]
  • High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy : a large retrospective analysis
    Moore RA J Clin Oncol 29 3466-3473 [2011]
  • Development and validation of a predictive model for chemotherapy-associated thrombosis
    Khorana AA Blood 111 : 4902 ~ 4907 [2008]
  • Development and validation of a predictive model for chemotherapy-associated thrombosis
    Khorana AA Blood 111 4902-4907 [2008]
  • Cisplatin-associated thrombosis
    Jafri M Anticancer Drugs 19 : 927 ~ 929 [2008]
  • Cisplatin-associated thrombosis
    Jafri M Anticancer Drugs 19 927-929 [2008]
  • Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer : results from a randomized phase III trial with 5 years' follow-up
    Sundstrom S J Clin Oncol 20 : 4665 ~ 4672 [2002]
  • Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer : results from a randomized phase III trial with 5 years' follow-up
    Sundstrom S J Clin Oncol 20 4665-4672 [2002]
  • Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity
    Lechner D J Thromb Haemost 5 : 2445 ~ 2452 [2007]
  • Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity
    Lechner D J Thromb Haemost 5 2445-2452 [2007]